🕒 Last update: loading…16/11/2026

Stock NRC Health NRC

NRC Health — Investlytic score 2/5 on the five criteria.

-
-
40/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 2/5 criteria met. Data as of 17/09/2026.

  • ❌ Price trend failed
  • ⚠️ Mixed growth
  • ❌ Debt failed
  • ✅ P/E passed
  • ✅ Correction passed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: 72.89%

Price change 2019 → 2020: -35.17%

Price change 2020 → 2021: -2.88%

Price change 2021 → 2022: -10.16%

Price change 2022 → 2023: 6.06%

Price change 2023 → 2024: -55.41%

Price change 2024 → 2025: 6.41%

Price change 2025 → 2026: 3.94%

Price change 2026 (year to date): 8.21%

Financial growth

Revenue CAGR (8 years): 1.99%

Earnings CAGR (8 years): -12.71%

Growth status: positive trend (>1%/yr) in revenue OR earnings, but not both.

Debt

Debt-to-equity ratio: 5.65

Debt/equity > 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: 24.82

P/E < 25.0 (maximum threshold).

Correction (6 months)

Current correction: 14.32% from the high over 6 months.

Correction between 10.0% and 20.0% (target range).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
National Research Corporation31.55.65+5.3 %🔒
Lumibird S.A.38.10.71+9.8 %–
Valneva SE–1.95+22.4 %–
4D Molecular Therapeutics, Inc.–0.04+40.0 %–
Equasens S.A.10.60.21+6.5 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by NRC Health over the latest fiscal years.

Revenue
137 m USD
fiscal year 2025
Net income
11.6 m USD
fiscal year 2025
Net margin
8.4 %
fiscal year 2025
Average annual growth
+0.6 %
Revenue growth over 5 years
Average annual growth
+3.0 %
Revenue growth over 10 years
Market cap
564 m USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
2020133 m37.3 m28.0 %n/a
2021148 m37.5 m25.3 %+11.0 %
2022152 m31.8 m21.0 %+2.4 %
2023149 m31.0 m20.8 %-2.0 %
2024143 m24.8 m17.3 %-3.7 %
2025137 m11.6 m8.4 %-4.0 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by NRC Health over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
average accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
3.33
safe zone (above 2.99)
Piotroski Score
7 / 9
7 to 9: solid accounts
DCF Value
11.70 USD
DCF below share price · share price 27.29 USD, gap -57.1 %
Net Debt / EBITDA
4.05 x
high debt
Fiscal year20212022202320242025
Cash and investments54.4 m25.0 m6.7 m4.2 m4.1 m
Total Debt28.7 m23.4 m39.0 m64.4 m79.0 m
Net Debt-25.7 m-1.6 m32.3 m60.2 m74.9 m
Equity85.3 m72.0 m49.0 m31.3 m14.0 m
Total assets158 m130 m122 m133 m135 m
Operating cash flow46.3 m36.3 m38.1 m34.6 m26.4 m
Investments (capex)5.5 m9.8 m15.8 m15.4 m10.7 m
Free cash-flow40.8 m26.4 m22.3 m19.2 m15.7 m
Share buybacks4.1 m27.6 m19.1 m30.9 m20.2 m
Dividends paid9.2 m21.0 m36.4 m11.5 m11.0 m

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)88.07 x
Price / book value-63.44 x
Return on Equity (ROE)103.4 %
Return on Invested Capital (ROIC)9.5 %
Net margin4.5 %
Debt / equity-11.28 x
Current ratio0.64 x
Interest coverage2.90 x
Free cash-flow yield3.3 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 16/11/2026.

+

Valuation and competitors

NRC Health compared with its sector on the same exchange and with its main competitors.

Company P/E
32.4
55.6 % above the sector
Sector median P/E
20.8
healthcare, Nasdaq
Sector over 10 years
28.2
10-year median, range 20.4 to 45.8

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 23/05/2013
ISIN code
US6373722023
Workforce
368
full-time employees
Chief executive
Michael D. Hays

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about NRC Health

What is the NRC Health share price?

Latest recorded price: 26.56 USD on 13/11/2026, for a market cap of 564 m USD.

What is the revenue of NRC Health?

137 m USD for fiscal year 2025, with net income of 11.6 m USD (net margin 8.4 %).

What is the P/E ratio of NRC Health?

Trailing 12-month P/E of 32.4, against 20.8 for the sector median on the same exchange (10-year median: 28.2).

Is NRC Health stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US6373722023).

How many employees does NRC Health have?

368 full-time employees according to the latest published profile.

Who runs NRC Health?

Michael D. Hays is the company's chief executive.

07

Similar stocks